Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 2/20 | 0.52 |
| ▸ | HTT | P42858 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | CES2 | O00748 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | USP2 | O75604 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | CES1 | P23141 | 1/20 | 0.43 |
| ▸ | FAAH | O00519 | 1/20 | 0.41 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.39 |
| ▸ | LPAR3 | Q9UBY5 | 3/20 | 0.39 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.39 |
| ▸ | LPAR2 | Q9HBW0 | 2/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11611495 | 1.00 | THRB (0.52) | THRBHTTMEN1KMT2AMAPT | |
| SCHEMBL23567318 | 1.00 | THRB (0.52) | THRBHTTMEN1KMT2AMAPT | |
| SCHEMBL503324 | 1.00 | THRB (0.52) | THRBHTTMEN1KMT2AMAPT | |
| SCHEMBL23567291 | 1.00 | THRB (0.52) | THRBHTTMEN1KMT2AMAPT | |
| SCHEMBL23567325 | 1.00 | — | — | |
| SCHEMBL8805127 | 0.97 | — | — | |
| SCHEMBL671834 | 0.88 | — | — | |
| SCHEMBL21044684 | 0.82 | THRB (0.70) | THRBHTTMEN1KMT2AMAPT | |
| SCHEMBL21828421 | 0.82 | THRB (0.70) | THRBHTTMEN1KMT2AMAPT | |
| SCHEMBL21044719 | 0.82 | THRB (0.70) | THRBHTTMEN1KMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12048682-B2 | Combination of micheliolide derivatives or nanoparticles with ionizing radiation and checkpoint inhibitors for cancer therapy | THE UNIVERSITY OF CHICAGO (US) | 2024-07-30 | — | — | US | disclosed |
| US-20230036839-A1 | COMBINATION OF MICHELIOLIDE DERIVATIVES OR NANOPARTICLES WITH IONIZING RADIATION AND CHECKPOINT INHIBITORS FOR CANCER THERAPY | THE UNIVERSITY OF CHICAGO (US) | 2023-02-02 | — | — | US | disclosed |
| US-20230036839-A1 | COMBINATION OF MICHELIOLIDE DERIVATIVES OR NANOPARTICLES WITH IONIZING RADIATION AND CHECKPOINT INHIBITORS FOR CANCER THERAPY | THE UNIVERSITY OF CHICAGO (US) | 2023-02-02 | — | — | US | disclosed |
| US-11389422-B2 | Combination of micheliolide derivatives or nanoparticles with ionizing radiation and checkpoint inhibitors for cancer therapy | THE UNIVERSITY OF CHICAGO (US) | 2022-07-19 | — | — | US | disclosed |
| US-20200261403-A1 | COMBINATION OF MICHELIOLIDE DERIVATIVES OR NANOPARTICLES WITH IONIZING RADIATION AND CHECKPOINT INHIBITORS FOR CANCER THERAPY | THE UNIVERSITY OF CHICAGO | 2020-08-20 | — | — | US | disclosed |
| US-20190314324-A1 | COMBINATION OF MICHELIOLIDE DERIVATIVES OR NANOPARTICLES WITH IONIZING RADIATION AND CHECKPOINT INHIBITORS FOR CANCER THERAPY | THE UNIVERSITY OF CHICAGO | 2019-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190314324-A1 | COMBINATION OF MICHELIOLIDE DERIVATIVES OR NANOPARTICLES WITH IONIZING RADIATION AND CHECKPOINT INHIBITORS FOR CANCER THERAPY | MCL1, CD274, PDCD1 | THRB 4562/4885HTT 2447/4885MEN1 98/4885 |
| US-20230036839-A1 | COMBINATION OF MICHELIOLIDE DERIVATIVES OR NANOPARTICLES WITH IONIZING RADIATION AND CHECKPOINT INHIBITORS FOR CANCER THERAPY | MCL1, CD274, PDCD1 | THRB 4562/4885HTT 2447/4885MEN1 98/4885 |
| US-11389422-B2 | Combination of micheliolide derivatives or nanoparticles with ionizing radiation and checkpoint inhibitors for cancer therapy | MCL1, CD274, PDCD1 | THRB 4562/4885HTT 2447/4885MEN1 98/4885 |
| US-12048682-B2 | Combination of micheliolide derivatives or nanoparticles with ionizing radiation and checkpoint inhibitors for cancer therapy | MCL1, CD274, PDCD1 | THRB 4562/4885HTT 2447/4885MEN1 98/4885 |
| US-20200261403-A1 | COMBINATION OF MICHELIOLIDE DERIVATIVES OR NANOPARTICLES WITH IONIZING RADIATION AND CHECKPOINT INHIBITORS FOR CANCER THERAPY | MCL1, CD274, PDCD1 | THRB 4562/4885HTT 2447/4885MEN1 98/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.